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MaOBJECTIVES This study sought to investigate whether the presence of J waves was associated with cardiac events in
patients with hypertrophic cardiomyopathy (HCM).
BACKGROUND It has been uncertain whether the presence of J waves predicts life-threatening cardiac events in
patients with HCM.
METHODS This study evaluated consecutive 338 patients with HCM (207 men; age 61  17 years of age). A J-wave was
deﬁned as J-point elevation >0.1 mV in at least 2 contiguous inferior and/or lateral leads. Cardiac events were deﬁned as
sudden cardiac death, ventricular ﬁbrillation or sustained ventricular tachycardia, or appropriate implantable cardiac
deﬁbrillator therapy. The study also investigated whether adding the J-wave in a conventional risk model improved a
prediction of cardiac events.
RESULTS J waves were seen in 46 (13.6%) patients at registration. Cardiac events occurred in 31 patients (9.2%)
duringmedian follow-upof 4.9years (interquartile range: 2.6 to 7.1 years). In a Coxproportional hazardsmodel, thepresence
of J waves was signiﬁcantly associated with cardiac events (adjusted hazard ratio: 4.01; 95% conﬁdence interval [CI]: 1.78 to
9.05; p ¼ 0.001). Compared with the conventional risk model, the model using J waves in addition to conventional risks
better predicted cardiac events (net reclassiﬁcation improvement, 0.55; 95% CI: 0.20 to 0.90; p ¼ 0.002).
CONCLUSIONS The presence of J waves was signiﬁcantly associated with cardiac events in HCM. Adding J waves to
conventional cardiac risk factors improved prediction of cardiac events. Further conﬁrmatory studies are needed
before considering J-point elevation as a marker of risk for use in making management decisions regarding risk in patients
with HCM. (J Am Coll Cardiol EP 2017;3:1136–42) © 2017 by the American College of Cardiology Foundation.H ypertrophic cardiomyopathy (HCM) isassociated with sudden cardiac death(SCD), particularly in young people (1). For
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Author's Personal Copyelectrocardiogram (ECG), is often found in the general
population and was previously considered a benign
ﬁnding. However, Haïssaguerre et al. (3) demon-
strated that the presence of J waves in an inferolateral
lead was likely associated with idiopathic ventricular
ﬁbrillation (VF). More current studies demonstrated
that the presence of J waves was associated with
life-threatening arrhythmic events and a worse prog-
nosis in patients with Brugada syndrome (4), ischemic
heart disease (5,6), or long-QT syndrome (7).SEE PAGE 1143
FIGURE 1 Study Enrollment and Flow of Patients With HCM
HCM ¼ hypertrophic cardiomyopathy.
IDI = integrated discrimination
improvement
Ito = transient outward current
LV = left ventricular




SCD = sudden cardiac death
VF = ventricular ﬁbrillation
VT = ventricular tachycardiaFew studies have reported the relationship be-
tween J waves and cardiac events in patients with
HCM (8,9). However, it remains uncertain whether
the presence of J waves also predicts lethal
arrhythmic events or a poor prognosis in patients
with HCM. Here we evaluated whether the presence
of J waves was associated with life-threatening car-
diac events in patients with HCM. In addition, we
assessed whether the modiﬁed risk model, using the
presence of J waves with conventional risk factors,
better predicted the cardiac events compared with
the conventional risk model.
METHODS
STUDY POPULATION. From January 1991 to January
2015, we registered 389 consecutive patients with
HCM at Kanazawa University Hospital and its afﬁli-
ated hospitals in Kanazawa, Japan. We excluded 51 of
those patients (40 with left or right bundle branch
block or ventricular pacing rhythm and 11 with
insufﬁcient clinical information). A total of 338 pa-
tients were retrospectively evaluated (Figure 1). This
study observed the principles outlined in the Decla-
ration of Helsinki and was approved by the Ethics
Committee for Medical Research at Kanazawa Uni-
versity Hospital. All study patients provided written
informed consent before study registration.
We divided these patients into 2 groups: 1
including patients with J waves in the inferior and/or
lateral leads (J-wave group: n ¼ 46); and the other
including patients without J waves (non–J-wave
group: n ¼ 292) (Figure 1, Table 1).
HCM DEFINITIONS. The clinical diagnosis of HCMwas
made on the basis of the 2011 joint guidelines of the
American College of Cardiology Foundation and the
American Heart Association (2). In brief, the criterion
was the presence of a nondilated and hypertrophied
left ventricle on 2-dimensional echocardiography
(wall thickness $13 mm) in the absence of another
disease that could account for the hypertrophy.End-stage HCM was deﬁned as a left ventric-
ular (LV) ejection fraction <50% observed on
by 2-dimensional echocardiography (10). HCM
coexisting with hypertension was not
excluded in this study. With the ﬁnding of at
least 1 sarcomere gene mutation, we diag-
nosed HCM as genotype-positive, phenotype-
negative preclinical HCM, even if ventricular
hypertrophy was absent (11).
ECG ASSESSMENT. A standard 12-lead ECG
was recorded at a paper speed of 25 mm/s
with ampliﬁcation of 10 mm/mV in all cases.
The J-wave was deﬁned as an elevation in the
QRS-ST junction (J-point) of at least 0.1 mV in
at least 2 contiguous inferior (II, III, and aVF)
and/or lateral (I, aVL, and V6) leads (12). As
previously reported (13), we classiﬁed J-wave
morphology as a notching or slurring pattern.
Notching was deﬁned as a positive J deﬂection
at the end of the QRS complex (Figure 2A), and
slurring was deﬁned as a slower terminal
waveform transitioning from the QRS J-point to the
ST-segment (Figure 2B). We classiﬁed ST-segment
morphology after the J-point as horizontal or
ascending (13,14). All ECGs were analyzed by 2 inde-
pendent cardiologists (T.T., K.H.) who were blinded to
the patients’ characteristics or outcome data.
ECHOCARDIOGRAPHY. All echocardiographic parame-
ters were evaluated according to the guidelines of the
American Society of Echocardiography (15). Standard
2-dimensional and M-mode echocardiography was
performed using standard methods. LV end-diastolic
and end-systolic dimensions were recorded from
M-mode imaging obtained in the parasternal
TABLE 1 Clinical and Electrocardiographic or Echocardiographic Characteristics of






(n ¼ 292) p Value
Age, yrs 62  17 61  16 62  17 0.63
Male 207 (61) 31 (67) 176 (60) 0.42
SCD family history 39 (11.5) 5 (10.9) 34 (11.6) 0.88
Unexplained syncope 32 (9.5) 5 (10.9) 27 (9.3) 0.79
Documented NSVT 94 (27.8) 12 (12.8) 82 (28.1) 0.86
Documented AF 98 (29.0) 9 (19.6) 89 (30.5) 0.16
ICD 37 (10.9) 6 (13.0) 31 (10.6) 0.61
BNP, pg/ml 262  309 222  416 284  346 0.32
Heart rate, beats/min 64  11 66  12 64  11 0.19
PR interval, ms 171  32 167  26 172  33 0.30
QRS duration, ms 104  14 102  12 104  14 0.32
QTc interval, ms 429  23 425  20 431  23 0.15
SV1 þ RV5 leads, mV 4.1  1.7 4.1  1.3 4.1  1.8 0.99
Presence of J-wave 46 (13.6) — — —
J-wave amplitude, mV 0.26  0.09 — — —
Maximal wall thickness $30 mm 8 (2.4) 0 (0.0) 8 (2.7) 0.60
LVOTPG >30 mm Hg 56 (16.6) 7 (15.2) 49 (16.8) 0.79
LVEF, % 67.0  12.1 67.9  12.7 66.8  12.0 0.55
LA diameter, mm 43.3  7.5 43.9  6.5 43.3  7.6 0.56
Values are mean  SD or n (%), unless otherwise speciﬁed.
AF ¼ atrial ﬁbrillation; BNP ¼ B-type natriuretic peptide; HCM ¼ hypertrophic cardiomyopathy; ICD ¼
implantable cardioverter-deﬁbrillator; LA ¼ left atrial; LVEF ¼ left ventricular ejection fraction; LVOTPG ¼ left
ventricular outﬂow tract pressure gradient; NSVT ¼ nonsustained ventricular tachycardia; SCD ¼ sudden
cardiac death.
FIGURE 2 Representative ECG of J Waves in HCM
(A) Notched J waves in inferior leads and a horizontal ST-segment after a J-wave
(solid arrows). (B) Slurred Jwaves in inferior leads and a rapidly ascending ST-segment after
a J-wave (dashed arrows). ECG¼ electrocardiogram; HCM¼ hypertrophic cardiomyopathy.
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Author's Personal Copywindows at the level of the mitral leaﬂet. LV ejection
fraction was determined using the modiﬁed Simpson
method. Left atrial diameter was recorded in the
parasternal windows, and left atrial volume was
measured by the Simpson method, by using
4-chamber and apical 2-chamber views at ventricular
end-systole. LV wall thickness was measured in the
end-diastolic phase by using 2-dimensional images at
the level of the mitral valve and papillary muscles.
Maximum wall thickness was deﬁned as the greatest
thickness within the chamber (16). Continuous wave
Doppler imaging was used to measure maximal
velocity across the LV outﬂow tract at rest and during
a Valsalva maneuver. The pressure gradient was
calculated using the simpliﬁed Bernoulli equation.
A peak pressure gradient >30 mm Hg was regarded as
LV outﬂow obstruction (17).
STUDY ENDPOINTS. We deﬁned cardiac events as
follows: an occurrence of SCD; documentation of VF
or sustained ventricular tachycardia (VT) in ECG
monitoring, Holter recording, or telemetry data; or
appropriate ICD therapy. SCD is an unexpected death
from a cardiac cause occurring within 1 h of symptom
onset or witnessed unexpected death. A family history
of SCD means a history of SCD in 1 or more ﬁrst-degree
relatives younger than 40 years of age or SCD in a ﬁrst-
degree relative with conﬁrmed HCM at any age (18).
NSVT means 3 or more consecutive ventricular
beats $100 beats/min with a duration #30 s. Appro-
priate ICD therapy refers to shock or antitachycardia
pacing therapy for a response of VF or sustained VT.
All interrogated ICD data were checked by cardiolo-
gists, who determined whether ICD therapies were
appropriate. Follow-up for clinical endpoints was
performed by review of outpatient or inpatient
medical records in Kanazawa University Hospital and
its afﬁliated hospitals, telemetry data from cardiac
devices, and routine recorded ECGs until September
2016. We tracked an event of death or lethal
arrhythmic event that occurred outside our hospital by
telephone check to patients’ families or by ﬁnding
remote monitoring systems installed in cardiac
devices.
STATISTICAL ANALYSIS. Continuous variables were
compared using the Student t test for paired data.
Categorical variables were compared using the
Fisher exact test. Adjusted hazard ratios (HRs) and
corresponding 95% conﬁdence intervals (CIs) of
each variables associated with cardiac events were
calculated by a Cox proportional hazards model.
To investigate differences between groups in the
cumulative ratio for cardiac events, the occurrence of
cardiac events was presented using Kaplan-Meier
TABLE 2 Clinical and Electrocardiographic Or Echocardiographic
Characteristics of Patients With HCM (Differences Between
Groups With and Without Cardiac Events)
Cardiac Event
(þ) (n ¼ 31)
Cardiac Event
() (n ¼ 307) p Value
Age, yrs 63  14 62  17 0.74
Male 20 (65) 187 (61) 0.84
SCD family history 10 (32.3) 29 (9.5) 0.0010
Unexplained syncope 10 (32.3) 22 (7.2) 0.0002
Documented NSVT 15 (48.4) 79 (25.7) 0.01
Documented AF 14 (45.2) 84 (27.4) 0.06
ICD 22 (70.9) 15 (4.9) <0.0001
BNP, pg/ml 350  351 253  304 0.14
Heart rate, beats/min 62  9 64  11 0.33
PR interval, ms 176  36 171  32 0.39
QRS duration, ms 108  10 103  14 0.09
QTc interval, ms 437  20 429  23 0.08
SV1 þ RV5 leads, mV 3.9  2.1 4.2  1.7 0.48
Presence of J waves 11 (35.5) 35 (11.4) 0.001
J-wave amplitude, mV 0.27  0.13 0.25  0.07 0.67
J waves in inferior or
lateral lead
6 (19.4) 32 (10.4) 0.14
J waves in inferior and
lateral lead
5 (16.1) 3 (1.0) 0.002
Notching J waves 9 (29.0) 18 (5.9) 0.0002
Slurred J waves 3 (9.7) 16 (5.2) 0.40
Horizontal ST-segment 9 (29.0) 19 (6.2) 0.0003
Ascending ST-segment 3 (9.7) 15 (4.9) 0.22
Maximal wall thickness
$30 mm
2 (6.5) 6 (2.0) 0.16
LVOTPG >30 mm Hg 9 (29.0) 47 (15.3) 0.07
LVEF, % 63.0  14.2 67.4  11.8 0.06
LA diameter, mm 45.3  7.5 43.1  7.4 0.12
Values are mean  SD or n (%), unless otherwise speciﬁed.
Abbreviations as in Table 1.
TABLE 3 Multivariate Cox Proportional Regression Model in Patients
With HCM
Model 1 Model 2
HR (95% CI) p Value HR (95% CI) p Value
Age 1.01 (0.99–1.04) 0.28 1.02 (0.99–1.05) 0.16
Male 1.33 (0.64–2.89) 0.45 1.33 (0.61–2.88) 0.47
SCD family history — — 2.73 (1.19–6.26) 0.017
Unexplained syncope — — 2.80 (1.20–6.53) 0.018
Documented NSVT — — 2.10 (0.93–4.74) 0.07
Maximal wall
thickness $30 mm
— — 6.43 (1.17–35.2) 0.032
Presence of J waves 3.18 (1.45–6.65) 0.005 4.01 (1.78–9.05) 0.001
CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Table 1.
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Author's Personal Copycumulative survival curves and compared using the
log-rank test. A p value of <0.05 was considered sta-
tistically signiﬁcant. We also used net reclassiﬁcation
improvement (NRI, continuous method), and inte-
grated discrimination improvement (IDI) to compare
the modiﬁed risk model including the presence of
J waves with the conventional risk model. All statis-
tical analyses were performed using JMP Pro software
version 11 (SAS Institute, Cary, North Carolina), or
R version 3.3.1 (The R Foundation, Vienna, Austria).
RESULTS
BASELINE CHARACTERISTICS. Baseline characteris-
tics are shown in Table 1. We evaluated consecutive
338 patients with HCM in this study. A total of 207
patients (61%) were male, and the mean age was 62 
17 years. A total of 39 patients (11.5%) had a family
history of SCD, and 32 (9.5%) patients hadunexplained syncope. NSVT was documented in 94
(27.8%) patients, and atrial ﬁbrillation (paroxysmal,
persistent, or permanent) was noted in 98 (29.0%)
patients at baseline. A total of 37 patients (10.9%) had
ICD implantation. From the echocardiographic data,
extreme LV hypertrophy ($30 mm) was seen in only 8
(2.4%) patients, LV ejection fraction was 67.0  12.1%,
and LV outﬂow obstruction was found in 56 (16.6%)
patients. We then compared patients with HCM by
the presence or absence of J waves (Table 1). There
were no signiﬁcant differences in patients’ charac-
teristics and electrocardiographic and echocardio-
graphic parameters at baseline between them.
CARDIAC EVENTS IN HCM. During follow-up, cardiac
events occurred in 31 (9.2%) patients (6, SCD; 25,
appropriate ICD shock triggered by VF or sustained
VT, or documented VF or sustained VT). Table 2 shows
the details of clinical proﬁles, including risk factors
along with ﬁndings on ECGs and echocardiographic
studies, as well as J-wave morphology and its location
in the ECGs, for the 31 patients with cardiac events and
for 307 patients without cardiac events. As expected,
the established risk factors for HCM (e.g., a family
history of SCD, unexplained syncope, and docu-
mented NSVT) were more frequently observed in the
cardiac event group than in the nonevent group.
Notably, J waves were more frequently seen in the
event group than in the nonevent group (35.5% vs.
11.4%; p ¼ 0.001). Furthermore, J waves in the inferior
and lateral leads, notched J waves, and J waves with a
horizontal ST-segment were also more frequent in the
event group than in the nonevent group.
THE PRESENCE OF J WAVES PREDICTS CARDIAC
EVENTS. We tested whether the presence of J waves
was useful to predict life-threatening arrhythmic
events. In a Cox proportional hazards model, the
presence of J waves was signiﬁcantly associated with
FIGURE 3 Lethal Ventricular Arrhythmia Event-Free Survival Rate Between the Group
With J Waves in Any Location and the Non–J-Wave Group
Kaplan-Meier analysis showing cardiac events in the non–J-wave group (red) and in the
group with J waves in any location (blue). The number of patients at risk during follow-up
is shown below the abscissa. J waves in any location were associated with worse event-free
survival than no J-wave.
FIGURE 4 Lethal V
the J-Wave Distribu
Kaplan-Meier analys
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Author's Personal Copycardiac events adjusted by age and sex (adjusted HR:
3.18; 95% CI: 1.45 to 6.65; p ¼ 0.005) (Table 3, model 1).
Even adjusted by SCD-related conventional risk
factors, the presence of J waves was an independententricular Arrhythmia Event-Free Survival Rate With Respect to
tion on ECG
is showing cardiac events in patients with no J-wave (red), J waves
eral leads (green), and J waves in both inferior and lateral leads
r of patients at risk during follow-up is shown below the abscissa.
gram.predictor of cardiac events (adjusted HR: 4.01; 95% CI:
1.78 to 9.05; p ¼ 0.001) (Table 3, model 2). Unadjusted
Kaplan-Meier analysis showed that patients with
HCM who had J waves had worse event-free survival
rates than did patients with HCM without J waves
(Figures 3 and 4). Event-free survival tended to be
lower in patients with J waves in both inferior and
lateral leads compared with patients with J waves
only in inferior or lateral leads (Figure 4).
ADDING THE PRESENCE OF J WAVES IMPROVED
PREDICTION OF CARDIAC EVENTS. We also investi-
gated whether adding the presence of J waves with
conventional risks (modiﬁed risk model) improved the
prediction of cardiac events in patients with HCM.
We compared the conventional risk model (only
including SCD conventional risk factors) with the
modiﬁed risk model using NRI and IDI. The modiﬁed
risk model signiﬁcantly improved the prediction of
cardiac events compared with the conventional risk
model: NRI, 0.55 (95% CI: 0.20 to 0.90; p ¼ 0.002); and
IDI, 0.09 (95% CI: 0.02 to 0.16; p ¼ 0.015) (Table 4).
DISCUSSION
In this study, we investigated whether a J-wave could
be a potential predictor of life-threatening cardiac
events in patients with HCM. The main ﬁndings of our
study are as follows: 1) the presence of J waves in
addition to established risk markers of SCD was
associated with cardiac events in patients with HCM;
and 2) the modiﬁed risk model adding J waves to
conventional SCD risk factors could better predict
cardiac event in patients with HCM than the
conventional risk model alone.
We demonstrated that the presence of J waves
was signiﬁcantly linked to lethal cardiac events in
patients with HCM. In the Kaplan-Meier subgroup
analysis of the J-wave group, the distribution only in
inferior or lateral leads in addition to both leads was
signiﬁcantly associated with cardiac events in
patients with HCM. Previously, Li et al. (8) reported
that J waves were signiﬁcantly more common in
patients with sudden cardiac arrest in HCM. Addi-
tionally, Naruse et al. (9) reported that, by using Cox
regression model, the presence of J waves was an
independent predictor of the occurrence of appro-
priate device therapy in patients with nonischemic
cardiomyopathy who underwent ICD implantation.
Unlike these 2 studies, we showed that the presence
of J waves was independently associated with lethal
arrhythmic events even after adjustment by conven-
tional SCD risk markers of HCM.
We also pointed out that the model adding the
presence of J waves to conventional risk markers











in Modiﬁed Model Total
Event cases (VT/VF/SCD) 4 (13)* 23 (74) 4 (13)† 31
Nonevent cases 156 (51)† 124 (40) 27 (9)* 307
Values are n (%). NRI (categorical) [95% CI]: 0.4202 [0.2272–0.6131]; p ¼ 0.00002. NRI (continuous) [95% CI]:
0.5462 [0.196–0.8964]; p ¼ 0.00224. IDI [95% CI]: 0.0889 [0.0176–0.1602]; p ¼ 0.01449. *Incorrect
reclassiﬁcation in the new model. †Correct reclassiﬁcation in the new model.
IDI ¼ integrated discrimination improvement; NRI¼ net reclassiﬁcation improvement; VT/VF/SCD¼ ventricular
tachycardia/ventricular ﬁbrillation/sudden cardiac death.
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cardiac events in patients with HCM. The American
College of Cardiology Foundation/American Heart
Association guidelines recommend that patients with
HCM should undergo SCD risk stratiﬁcation on the
basis of the following: their family history of SCD in
ﬁrst-degree relatives <40 years of age; maximal LV
wall thickness of >30 mm; unexplainable syncope;
past history of VF, sustained VT, or SCD events; and
abnormal BP response during exercise (2). The Japa-
nese Circulation Society guidelines also recommend
that patients with HCM who have these conventional
risk factors should undergo ICD therapy (19). The
European Society of Cardiology guidelines have rec-
ommended a risk prediction model for SCD in HCM
that uses most of these risk factors as its basis, com-
bined with LV outﬂow tract gradient, left atrial
diameter, and age at evaluation (the HCM Risk-SCD
model) (18). From this study, it might be worth
including the presence of J waves as an additional
risk factor for SCD in patients with HCM.
Haïssaguerre et al. in 2008 (3) deﬁned early repo-
larization as an elevation of the QRS-ST junction
(J-point) in at least 2 consecutive leads. An elevation
of the QRS-ST junction can be a product of transient
outward current (Ito)–mediated J waves, repolariza-
tion component, or ventricular conduction delay
from depolarization abnormalities (20). Ito-mediated
J waves are usually seen in young adults and
commonly exist in combination with upwardly
concave ST-segment elevation. Ito-mediated J waves
always initiate arrhythmia from a short-coupled pre-
mature ventricular beat on T waves and causes
polymorphic VT or VF. In contrast, ventricular con-
duction delay from depolarization abnormalities is
usually seen in older adults with structural heart
disease and often causes premature ventricular beats
after T-wave and monomorphic arrhythmia. These 2
manifestations on ECGs can be distinguished on the
basis of their response rate. Faster rates or premature
beats can accentuate the notching caused by delayed
conduction, and they can attenuate the J waves
caused by repolarization defects (21). In patients with
HCM, intraventricular conduction delay is often
observed and can partly play a role in the occurrence
of J waves. We performed cardiac magnetic resonance
(CMR) (n ¼ 178; 52.7%) in our patients with HCM;
results showed delayed enhancement in 72% of
patients. There was no signiﬁcant association
between the presence of J waves and the frequency of
detection of delayed enhancement, which reﬂects
myocardial scar, a cause of depolarization abnormal-
ity. J waves in HCM might be caused by both repo-
larization and depolarization abnormalities.The intraventricular conduction delay in HCM is
also known to initiate notching of the QRS complex
(fragmented QRS complex) (21). We and others (22,23)
reported that the presence of fragmented QRS
complexes, deﬁned as the presence of an additional
R-wave (R0), notching in the nadir of the S-wave, or the
presence of >1 R0 on the 12-lead ECG, was associated
with either heart failure with hospitalization or
arrhythmic events in patients with HCM. We also
showed, using late gadolinium enhancement in CMR,
that fragmented QRS complexes can be markers
of myocardial ﬁbrosis in patients with HCM (24).
Notably, it is sometimes difﬁcult to distinguish
notched J waves from notching in the nadir of the
S-wave because of the overlap in their deﬁnitions.
Further studies will demonstrate the pathophysiolog-
ical roles of J waves in the appearance of a clinical
phenotype and a difference from the fragmented
QRS complex.
STUDY LIMITATIONS. First, CMR, signal-averaged
ECG, or T-wave alternans examinations were not
evaluated in this study. Further examination with the
combined use of these modalities would augment the
demonstration of J waves. Second, we excluded
patients with HCM who had abnormal conduction,
such as right or left bundle branch block, or ventric-
ular pacing rhythm, which could affect the results.
Third, to examine differences in the impact of
predicting cardiac events among J-wave subgroups
(distribution pattern on ECG, notched or slurred type,
horizontal or ascending ST-segment morphology),
these subgroups included very small numbers of
patients. Fourth, we evaluated conventional risks of
HCM without abnormal BP response during exercise
because we obtained results of the exercise stress test
from only a few study patients.
CONCLUSIONS
The presence of J waves was associated with life-
threatening arrhythmic events in patients with HCM
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: In
patients with HCM, the presence of J waves may be
useful for predicting lethal arrhythmic events, in
addition to established SCD risk factors. The clinician
should be vigilant concerning future arrhythmic events
in patients with HCM when J waves are found on their
ECGs.
TRANSLATIONAL OUTLOOK: This study
should stimulate future examination of the
noninvasive prediction of lethal arrhythmic
events in patients with HCM in a larger
prospective cohort.
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Author's Personal Copyin addition to a family history of SCD, unexplained
syncope, and severe LV hypertrophy. The modiﬁed
model adding the presence of J waves with conven-
tional risk markers better predicted cardiac events in
patients with HCM compared with the conventional
risk model. J waves may provide a useful tool for
evaluating future cardiac events in patients with HCM.
However, further conﬁrmatory studies are needed
before J-point elevation can be considered a marker of
risk for use in making management decisions
regarding risk in patients with HCM.
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